Table 1.

Study characteristics.

References, year	Study type	Number of patients	PPI (generic name)	PPI (number of patients)	Event number: MACE (PPI group)	Event number: CV death (PPI group)	Event number: MI (PPI group)
Ng et al., 2012	RCT	311	Esomeprazole	163	7
Yano et al., 2012	RCT	130	Omeprazole	65	8
Hsu et al., 2011	RCT	42	Esomeprazole	21	4
Ren et al., 2011	RCT	172	Omeprazole	86	22
Bhatt et al., 2010	RCT	3,761	Omeprazole	1,876	55	5	14
Cai et al., 2010	RCT	60	Omeprazole Pantoprazole	40	10
Gargiulo et al., 2016	RCT (post-hoc analysis)	1,970	Pantoprazole Lansoprazole Omeprazole, esomeprazole, rabeprazole	738 56 671 11	85	29	41
Burkard et al., 2012	RCT (post-hoc analysis)	801	Esomeprazole Pantoprazole Omeprazole	109 55 27 19	33	10	25
Goodman et al., 2012	RCT (post-hoc analysis)	9,276	Omeprazole Pantoprazole Esomeprazole Lansoprazole Rabeprazole	3,255 1,592 973 387 251 51	398	180	245
O'Donoghue et al., 2009	RCT (post-hoc analysis)	13,608	Omeprazole Pantoprazole Lansoprazole Esomeprazole	4,529 1,675 1,844 441 613	255
Ayub et al., 2016	Observational cohort	740	Omeprazole Esomeprazole Pantoprazole	332 40 81	30 6 10
Weisz et al., 2015	Observational cohort	8,581	NS	2,162	238	58	100
Hokimoto et al., 2014	Observational cohort	174	Rabeprazole	50	5
Shih et al., 2014	Observational cohort	2,703	NS	1,351			12
Zou et al., 2014	Observational cohort	7,653	Omeprazole Pantoprazole Esomeprazole	6,188 5,587 407 194	860	223	132
Chitose et al., 2012	Observational cohort	630	NS	187	7	4	1
Rossini et al., 2011	Observational cohort	1,328	Lansoprazole Pantoprazole Omeprazole	1,158 853 178 125	87
Simon et al., 2011	Observational cohort	2,353	Omeprazole Esomeprazole Pantoprazole Lansoprazole	1,453 993 311 99 46	43 20 12 1	94	24
Charlot et al., 2010	Observational cohort	24,702	NS	6,753	1058
Evanchan et al., 2010	Observational cohort	5,794	Esomeprazole Lansoprazole Omeprazole Pantoprazole	1,369 749 36 163 693			356
Gupta et al., 2010	Observational cohort	315	Rabeprazole, omeprazole, lansoprazole	72	40	14
Hudzik et al., 2010	Observational case-control	38	Omeprazole	18	10		6
Kreutz et al., 2010	Observational cohort	16,690	Omeprazole Pantoprazole Lansoprazole Esomeprazole	6,828 2,307 1,653 785 3257	1710
Ray et al., 2010	Observational cohort	16,221	Omeprazole Pantoprazole Lansoprazole, rabeprazole, esomeprazole	7,226 683 4,708	461
Stockl et al., 2010	Observational cohort	2,066	Pantoprazole Rabeprazole Omeprazole Lansoprazole Esomeprazole	1,033 659 159 86 83 46			133
van Boxel et al., 2010	Observational cohort	18,139	Omeprazole Pantoprazole Esomeprazole Rabeprazole Lansoprazole	5,734 1,826 2,618 1,092 133	754		84
Rassen et al., 2009	Observational cohort	18,565	Omeprazole, rabeprazole, esomeprazole, lansoprazole, pantoprazole	3,996		61	238

CV, cardiovascular; MACE, major adverse cardiac event; MI, myocardial infarction; NS, not shown/not specified; PPI, proton pump inhibitor; RCT, randomized controlled trial.